ArticleScientific reports2025
The clinicopathological and molecular landscape of breast cancer patients: a retrospective study in Sulaimaniyah, Iraq.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most common cancer among females and the second leading cause of cancer-related death in women, with different management modalities. To determine the premenopausal BC patients' clinicopathological and molecular landscape. This retrospective study was conducted on 300 primary BC patients aged 25-50 years at Hiwa Hematology and Oncology Hospital, Sulaimaniyah, Iraq, from January 2016 to May 2022. Patients underwent definitive management either before chemotherapy or after neo-adjuvant, and on regular follow-up. Patients were interviewed face to face using a well-designed questionnaire to collect the data, including the type of BC and hormonal status. In this study, most of the studied patients were married (90.3%), aged 45-50 years at diagnosis (36%), aged 13-14 years at the first occurrence of menstruation (70.3%), practised breastfeeding (76.7%), parous (85%), and with no surgical history (92%). Most patients (39%) had luminal B subtype, while the fewest (0.34%) had HER2 overexpression. The overall rate of breast-conserving surgery (BCS) was 66.7%, while the overall rate of mastectomy was 33.3% among patients. Also, 83.79% of the tumour margin was free, 9.03% was involved, and only 5.7% of the tumour margin was close. The tumour margin involved 20.3% and 15.6% of cases diagnosed with multifocal and multicentric tumour masses, respectively. It is concluded that married, aged, breastfed, and parous women showed the highest incidence of BC. The most prominent cancer subtype was luminal B, with the highest level of BCS. Most BC patients had a 2-5 cm, unifocal tumour mass with stage II-A disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.